Piri Çınar B.Tuncer A.Bilge N.Bünül S.D.Gözübatık-çelik R.G.Çiftçi E.D.Genç G.2024-03-092024-03-0920231301-062Xhttps://doi.org/10.4274/tnd.2023.16984https://search.trdizin.gov.tr/yayin/detay/1189506https://hdl.handle.net/20.500.14034/1638Multiple sclerosis (MS) is an autoimmune and demyelinating disease of the central nervous system. It is a chronic disease, and in the evaluation of all other health and vital processes, decisions about vaccination should be made considering the disease process and the medications used by the patient. Since vaccination can be performed at any stage of life, immune system activity should be reviewed in patients with MS except where it is characteristic of the vaccine. In this review, the applications of different vaccines in patients with MS are discussed in two separate sections (part 1 was published in the previous issue). © 2023 by the Turkish Neurological Society.eninfo:eu-repo/semantics/openAccessMultiple sclerosis; safety; vaccinationalemtuzumab; chickenpox vaccine; corticosteroid; fingolimod; hemagglutinin; influenza vaccine; ocrelizumab; ofatumumab; ravulizumab; rituximab; smallpox vaccine; teriflunomide; virus vaccine; antibody response; autoimmune disease; autoimmune disease of the central nervous system; cardiovascular disease; chronic kidney failure; condyloma acuminatum; demyelinating disease; disease activity; hemoglobinopathy; herd immunity; hospitalization; human; immune response; immunosuppressive treatment; liquorrhea; malaise; multiple sclerosis; myalgia; neuropathic pain; palliative therapy; papillomatosis; postherpetic neuralgia; Review; seroconversion; vaccination; viremiaReview Article10.4274/tnd.2023.1698429285942-s2.0-851636290641189506Q4